<DOC>
	<DOCNO>NCT01031498</DOCNO>
	<brief_summary>The goal clinical research study compare effectiveness 3 drug schedule prevent chemotherapy-related nausea and/or vomit patient acute myelogenous leukemia ( AML ) high-risk myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Palonosetron Versus Ondansetron Prevention Nausea Vomiting</brief_title>
	<detailed_description>Chemotherapy-related nausea vomit frequent problem among patient leukemia lead medical problem , malnutrition , dehydration , electrolyte imbalance , low quality life . Cytarabine , one drug use treat AML high-risk MDS , know cause nausea and/or vomit , patient receive chemotherapy cytarabine also need receive medication prevent side effect . One standard-of-care drug treat chemotherapy-related nausea vomit call Ondansetron . Palonosetron new drug similar Ondansetron design stay longer bloodstream . Researchers want find palonosetron prevent nausea vomit good ondansetron . Women able child must negative blood urine pregnancy test start treatment . If still eligible take part study , randomly assign ( roll dice ) one 3 treatment group . Participants first group give Ondansetron intravenous ( IV -- needle vein ) continuous infusion , 30 minute chemotherapy treatment 12 hour chemotherapy end . This consider standard care . Participants assign second treatment group give palonosetron day IV injection 5 day . Each dose give period 30 second , 30 minute chemotherapy treatment . Participants assigned third treatment group give palonosetron day IV injection , Days 1 , 3 , 5 chemotherapy treatment . Each dose give period 30 second , 30 minute chemotherapy treatment . No matter group assign , receive extra medication nausea and/or vomit need . You ask fill study diary daily 7 day , take long 10 minute complete . The diary use record number episode nausea and/or vomit experience study , well record need extra medication , help researcher learn 2 drug help best improve participant ' quality life ( sleep , daily activity , ability think reason ) . You take study intolerable side effect occur . This investigational study . The Food Drug Administration ( FDA ) approve palonosetron Ondansetron prevention chemotherapy-related nausea vomiting , drug commercially available . Up 150 participant take part study . All enrol UT MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1 . Patients &gt; 18 year acute myelogenous leukemia highrisk myelodysplastic syndrome undergo chemotherapy high dose cytarabine ( 1.5 2gm/m^2 ) containing regimen . 2 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . 1 . Patients emesis grade 2 nausea ( oral intake significantly decrease ) 3 nausea ( significant intake require intravenous fluid ) &lt; /= 24 hour chemotherapy . 2 . Patients ongoing emesis due organic etiology . 3 . Patients know hypersensitivity study drug selective 5HT3 receptor antagonist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>CINV</keyword>
	<keyword>Leukemia</keyword>
	<keyword>High-risk Myelodysplastic syndrome</keyword>
	<keyword>AML</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Hematologic Disorder</keyword>
	<keyword>Continuous multi-day chemotherapy</keyword>
	<keyword>High-dose cytarabine</keyword>
	<keyword>Palonosetron</keyword>
	<keyword>Aloxi</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>Zofran</keyword>
</DOC>